FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

FDA chief defends approval of Zohydro 'unique' pain drug

As pharmacies began dispensing Zogenix's powerful new painkillerZohydro this week, FDA Commissioner Margaret Hamburg found herself under increasing pressure to revoke her agency's approval of the drug and yank it off the market. But she's not about to cave in to the pressure, she told the U.S. Senate's Health, Education, Labor and Pensions Committee during a hearing on Thursday, according to Reuters.

"We recognize that this is a powerful drug, but we also believe that if appropriately used, it serves an important and unique niche with respect to pain medication and it meets the standards for safety and efficacy," Hamburg said.
Zohydro is the first all-hydrocodone pain reliever ever cleared by the FDA, making it the first approved pure opiate. And it doesn't have abuse- or tamper-resistant features to stop addicts from crushing it to get an immediate high. That has raised the hackles of a range of critics, from 28 state attorneys general who asked the FDA to withdraw Zohydro's approval in December, to the grassroots organization Fed Up! Coalition, which petitioned Hamburg to rethink her position on the drug in late February.

Following Thursday's hearing, Senator Joe Manchin (D-WV) introduced a bill to force the FDA to withdraw Zohydro from the market. The bill also would prohibit future approvals of painkillers that don't have tamper-resistant features. A similar law has been introduced in the House.

"Because of this painkiller's high potential for misuse and abuse, Zohydro poses a severely dangerous threat to our communities in West Virginia and across our country," Manchin said in a statement obtained by the AP. Hamburg said in a statement the FDA hasn't had a chance to review the proposed legislation. But she warned during the hearing that the technology for making painkillers resistant to abuse was still in its early stages, according to the AP.
"It doesn't do any good to label something as abuse deterrent if it isn't actually abuse deterrent, and right now, unfortunately, the technology is poor," Hamburg said.

In the midst of all the controversy, Purdue Pharma--the company that originally developed and sold the highly abused pain pill OxyContin--said it has finished a Phase III trial of its extended-release formulation of hydrocodone bitartrate, and that indeed it is abuse-deterrent. The once-daily pill was designed with tamper-resistant features, according to the company. Purdue plans to file to the FDA for approval later this year.


Go to Newer News Go to Older News